Tennor Therapeutics
PublicTennor Therapeutics is now publicly traded
The data on this page reflects Tennor Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series D
May 12, 2026
Total Funding Raised
$110.89M
Company Overview
Tennor Therapeutics operates in Biotech and is based in Suzhou, Jiangsu. It has raised $110.89M.
Tennor Therapeutics is a biotechnology research company that discovers and develops novel multi-functional drugs for the treatment of cancers and autoimmune diseases.
Sector
Biotech
AI Layer
Non-AI
Tennor Therapeutics Comparables
Compare Tennor Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gurnet Point Capital | 75% | |
| RedHill Biopharma | 73% | |
| Trellis Bioscience | 68% |
For institutional investors. Book with your work email.
Tennor Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 12, 2026 | ||||
| Series E | Oct 16, 2024 | ||||
| Series D Extension | Jan 5, 2023 | ||||
| Series D | Feb 25, 2022 | ||||
| Series C Extension | Jun 5, 2020 | ||||
Series B | Sep 19, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tennor Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 中山创业投资有限公司 | Series E |
| AMR Action Fund | Series E |
| Yuanjing Investment | Series D Extension |
| Yanchuang Capital | Series D |
| Oriza Holdings | Series C Extension, Series B, Series D |
| Al Mal Investment Company | Series B |
| Northern Light Venture Capital | Series B |
For institutional investors. Book with your work email.
Tennor Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.